Gossamer Bio Q3 2026 Earnings Date & Estimates

Gossamer Bio (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations.

Gossamer’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling. The therapy is being evaluated for pulmonary arterial hypertension, a serious and progressive disease affecting the blood vessels of the lungs. Seralutinib has advanced into late-stage clinical development, with the company seeking to establish its safety and efficacy as a potential treatment option.

The company has also developed additional programs targeting immune and inflammatory diseases, including investigational therapies directed at kinase and other disease-related pathways. Gossamer Bio was founded in 2015 and became a publicly traded company in 2019. Its research and development activities are focused primarily on the United States, while collaborations with international pharmaceutical companies support the potential development and commercialization of its therapies in global markets.

Faheem Hasnain, a co-founder of Gossamer Bio, has served as the company’s chairman and chief executive officer. The company’s strategy centers on advancing internally developed therapies through clinical trials and working with strategic partners to expand the reach of successful treatments.